News

Targeted Oncology14m
ASCO 2025: Clinical Efficacy From the COMMANDS Trial for Luspatercept in Lower-Risk MDS
An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...
Targeted Oncology20m
Perspectives of Early vs Late Initiation of ESAs for Patients With Lower-Risk MDS
An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...